|
Park News31 August 2006 Solexa Appoints Blain Bowman and Roy Whitfield to Board of DirectorsHAYWARD, Calif. and Cambridge, U.K. (August 30, 2006) – Solexa, Inc. (Nasdaq: SLXA) today announced the appointment of A. Blaine Bowman and Roy A. Whitfield to its Board of Directors. Mr. Bowman was formerly the chairman, president and chief executive officer and is currently a director of Dionex Corporation (Nasdaq: DNEX). Mr. Whitfield was co-founder and former chief executive officer of Incyte Corporation (Nasdaq: INCY). The Company also announced the resignation of Douglas Fambrough from its Board of Directors. “Blaine and Roy have extensive management experience in the life sciences industry,” said John West, chief executive officer of Solexa. “They have built companies from early-stage development to established, publicly-traded enterprises with significant revenue, cash and customer bases. We are delighted to have both Blaine and Roy as Solexa commercializes its first-generation instrument system.” Mr. Bowman, 60, retired as president and chief executive officer of Dionex, a leading developer and manufacturer of laboratory and process analytical systems for the environmental, pharmaceutical, life sciences and biotechnology industries, in July 2002 and as chairman of the board in 2005. He joined Dionex in 1977, when it was a one million dollar segment of a separate company and was named president and CEO in 1980. Under his leadership, Dionex reported increased sales and profits every year, generating $259 million in revenue in 2005. Before joining Dionex, Mr. Bowman was a management consultant with McKinsey & Company and a product engineer with Motorola Semiconductor Products Division. Mr. Bowman received his bachelor’s degree in physics from Brigham Young University and an M.B.A. from Stanford University. In addition to Dionex, he also serves on the boards of Cell BioSciences and Molecular Devices Corporation. Mr. Whitfield, 52, is the former chairman and chief executive officer of Incyte Corporation (formerly Incyte Genomics), a company he co-founded in 1991. Incyte was a pioneer and became a leader in the business of genomics, the large scale application of robotics and information technology in medical research and drug development. From 1993 to 2001, Mr. Whitfield served as its chief executive officer and from 2001 until 2003 as its chairman. In 1997, he was named Ernst & Young’s Northern California Entrepreneur of the Year for life sciences. Mr. Whitfield still serves on the Board of Incyte Corporation. Previously, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instruments company, and its predecessor company, Cooper Biomedical. Earlier, Mr. Whitfield spent seven years with the Boston Consulting Group's international consulting practice. Mr. Whitfield received his B.S. in Mathematics from Oxford University and his M.B.A. from Stanford University. In addition to serving on the Incyte board, he is a director of BioSeek, DiscoveRx, Nektar Therapeutics and Sciona. Mr. West added, “I would also like to extend my appreciation to Doug Fambrough, who joined our Board a year ago. His insights and perspective as a partner at Oxford Bioscience Partners and and as a genomics researcher have been extremely helpful to the Company. We wish Doug well in his future endeavors.” The appointment of Mr. Bowman and Mr. Whitfield brings the total number of directors on the Solexa board to seven.
|
|